Tolerance of Chemoradiation in Advanced Head and Neck Cancers: Comparison Between Inpatients and Outpatients
- 33 Downloads
Concurrent chemoradiation (CCRT) is the mainstay of treatment for majority of locally advanced head and neck carcinomas (LAHNC). Addition of chemotherapy to radiotherapy increases the probability of local control and improved disease-free survival but at the cost of acute and delayed toxicities. A retrospective observational study. To compare the tolerance of CCRT and its toxicity profile amongst two groups, first arm (Arm A) being outdoor patients and the second group (Arm B) was hospitalized patients of LAHNC in an oncology centre of a tertiary care hospital. A total of 100 patients were enrolled, 50 in each arm. Overall, the most common site was oropharynx, followed by larynx and hypopharynx. 38 patients in Arm A received full 6 cycles of weekly chemotherapy with Inj Cisplatin infusion. 39 of the hospitalized patients completed 6 cycles of weekly Cisplatin, 04 patients also received 3 weekly Cisplatin. Average duration of treatment was 49.18 days in arm A and 50.92 days in arm B. Incidence of Grade II onwards dysphagia was 48 and 45 (96 and 90%) in Arm A and Arm B respectively; Chi Square value—0.6 (Yate’s corrected); P value—0.43. Grade III oral mucositis was seen in 14% patients in Arm A and 34% patients in Arm B. 3 patients (6%) in Arm A and 14 patients (28%) in Arm B has Grade II and III hematological toxicities and nephrological toxicities. Aspiration pneumonia was seen in 2 patients (4%) in Arm A and in 4 patients (8%) in Arm B, Chi Square value—0.2 (Yate’s corrected) P value—0.67. The incidence of febrile neutropenia was 3 and 10 in Arms A and B (6 and 20%) respectively. The tolerance of CCRT in hospitalized patients is marginally better, with relatively few associated complications as compared to outdoor setting. Every institute should promulgate its own guidelines regarding hospitalization of such patients.
KeywordsHead and neck cancer Chemoradiation Toxicities Outpatient Hospitalization
The authors will like to thank Lt Col (Dr) Yadu Vir Singh MD (Community Medicine), PGD Epidemiology (PHFI) for his support in editing the manuscript and in providing statistical inputs.
Compliance with Ethical Standards
Conflict of interest
There is no conflict of interest to declare.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.
All patients were treated by the standard of care as per international guidelines and written informed consent was taken from all participants.
- 8.National Cancer Institute. Common toxicity criteria (NCI-CTC) v4.0. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf
- 12.Adelstein DJ, Li Y, Adams GL et al (2003) An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21:92–98. doi: 10.1200/JCO.2003.01.008 CrossRefPubMedGoogle Scholar
- 15.Fan KY, Gogineni H, Zaboli D, Lake S, Zahurak ML et al (2012) Comparison of acute toxicities in two primary chemoradiation regimens in the treatment of advanced head and neck squamous cell carcinoma. Ann Surg Oncol 19(6):1980–1987. doi: 10.1245/s10434-012-2219-4 CrossRefPubMedPubMedCentralGoogle Scholar
- 17.Bhide SA, Newbold KL, Harrington KJ, Nutting CM (1013) Clinical evaluation of intensity-modulated radiotherapy for head and neck cancers. Br J Radiol 2012(85):487–494Google Scholar
- 22.Zhang Z, Zhu Y, Ling Y, Zhang L, Wan H (2016) Comparative effects of different enteral feeding methods in head and neck cancer patients receiving radiotherapy or chemoradiotherapy: a network meta-analysis. Onco Targets Ther 9:2897–2909. doi: 10.2147/OTT.S101983 CrossRefPubMedPubMedCentralGoogle Scholar
- 23.Shaw SM, Flowers H, O’Sullivan B, Hope A, Liu LW et al (2015) The effect of prophylactic percutaneous endoscopic gastrostomy (PEG) tube placement on swallowing and swallow-related outcomes in patients undergoing radiotherapy for head and neck cancer: a systematic review. Dysphagia 30(2):152–175. doi: 10.1007/s00455-014-9592-z CrossRefPubMedGoogle Scholar
- 28.Madan R, Kairo AK, Sharma A, Roy S, Singh S et al (2015) Aspiration pneumonia related deaths in head and neck cancer patients: a retrospective analysis of risk factors from a tertiary care centre in North India. J Laryngol Otol 129(7):710–714. doi: 10.1017/S0022215115001450 CrossRefPubMedGoogle Scholar
- 34.Rawat S, Srivastava H, Ahlawat P, Pal M, Gupta G et al (2016) Weekly versus three-weekly cisplatin-based concurrent chemoradiotherapy as definitive treatment in head and neck cancer- where do we stand? Gulf J Oncol 1(21):6–11Google Scholar
- 35.Gupta T, Agarwal JP, Ghosh-Laskar S, Parikh PM, D’Cruz AK et al (2009) Radical radiotherapy with concurrent weekly cisplatin in loco-regionally advanced squamous cell carcinoma of the head and neck: a single-institution experience. Head Neck Oncol 15(1):17. doi: 10.1186/1758-3284-1-17 CrossRefGoogle Scholar